Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time.

Slides:



Advertisements
Similar presentations
A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Advertisements

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia 
Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.
How to Treat MDS without Stem Cell Transplantation
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Vaccination of Children following Allogeneic Stem Cell Transplantation
Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience 
Allogeneic Stem Cell Transplantation in Myelofibrosis
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.
Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted.
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Access to Hematopoietic Cell Transplantation in the United States
Do Patients and Physicians Agree When They Assess Quality of Life?
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Betty T. Tran, Abigail Halperin, Jason W. Chien 
Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,
J. J. Nietfeld, Marcelo C. Pasquini, Brent R
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Biology of Blood and Marrow Transplantation
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation  Lindsay G. Jensen, Tracey Stiller,
Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation  Navneet.
Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell.
Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation  Mats Remberger, Johan Törlén, Olle.
B Cells and Transplantation: An Educational Resource
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients  Irene Schmid, Daniel Stachel,
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation  Pere Barba, Jose Luis Piñana, David.
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia  Yu Wang,
A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host.
The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group  Amber B. Clemmons,
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Post-Thaw Viable CD45+ Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in.
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV?  Marie von Lilienfeld-Toal, MD, Maria Gilleece,
Blood and Marrow Transplant Handbook
A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation  Philippe Armand, Haesook.
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
Updated Experience with Inolimomab as Treatment for Corticosteroid-Refractory Acute Graft-versus-Host Disease  Irene García-Cadenas, David Valcárcel,
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Treatment versus Transplant for Challenging Hematologic Disorders
Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Presentation transcript:

Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value  Josep F. Nomdedéu, Albert Esquirol, Maite Carricondo, Marta Pratcorona, Montserrat Hoyos, Ana Garrido, Miguel Rubio, Elena Bussaglia, Irene García-Cadenas, Camino Estivill, Salut Brunet, Rodrigo Martino, Jorge Sierra  Biology of Blood and Marrow Transplantation  Volume 24, Issue 1, Pages 55-63 (January 2018) DOI: 10.1016/j.bbmt.2017.09.001 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Bone marrow WT1 levels before HCT identified 2 relevant groups based on a WT1 threshold of 100 copies: high WT1 (orange curves) and low WT1 (blue curves). Shown are the CIR (A), PFS (B), and OS (C), in days. Biology of Blood and Marrow Transplantation 2018 24, 55-63DOI: (10.1016/j.bbmt.2017.09.001) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Bone marrow WT1 levels at the first bone marrow aspirate after HCT. A 100-copy threshold identified 2 relevant groups: high WT1 (orange curves) and low WT1 (blue curves). Shown are CIR (A), PFS (B), and OS (C), in days. Biology of Blood and Marrow Transplantation 2018 24, 55-63DOI: (10.1016/j.bbmt.2017.09.001) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Bone marrow WT1 levels after HCT: relevance of the sustained levels below 100 copies. Shown are the CIR (A), PFS (B), and OS (C), in days. High WT1 is represented by orange curves; low WT1, by blue curves. Biology of Blood and Marrow Transplantation 2018 24, 55-63DOI: (10.1016/j.bbmt.2017.09.001) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.